VIP36’s Mouse Dose Separation Was Not a Human Cannabis Safety Margin
VIP36 showed substantial separation between pain-related efficacy and selected central side effects in mice. The reported separation was an experimental compound-specific result, not a safety ratio for THC products.
Molecular design and animal testing
Researchers designed a charged synthetic CB1 agonist to engage a receptor pocket while limiting brain penetration and arrestin recruitment. Structural, cellular and computational methods were combined with several mouse pain models. VIP36 is not THC or cannabis.
The repeated-treatment result was favorable
The compound retained anti-allodynic efficacy through the tested nerve-injury regimen and showed limited tolerance. Selected central adverse-effect measures required much higher doses than pain-related activity. These observations supported further development of the design strategy.
The denominator matters
A dose separation depends on the efficacy endpoint, adverse-effect endpoint, route and species. It cannot establish an equivalent margin for cognition, respiratory effects, every organ system or human dosing. Reduced arrestin recruitment was a proposed contributor to the favorable profile, not proof that this pathway alone explains every outcome. The study demonstrates a targeted drug-development approach while leaving clinical efficacy, exposure and safety to future patient research.
Related analysis: A Peripheral Cannabinoid Label Did Not Guarantee Freedom From Central Effects.
Primary research
A cryptic pocket in CB1 drives peripheral and functional selectivity. Nature (2025). DOI: 10.1038/s41586-025-08618-7.
